These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

90 related items for PubMed ID: 10658447

  • 1. [Intramuscular injections of PGE1 in patients with severe claudication].
    Corsi M, Laurora G, Cesarone MR.
    Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):59-63. PubMed ID: 10658447
    [Abstract] [Full Text] [Related]

  • 2. [European trial of PGE1 alpha cyclodextrin. Short-term vs. long-term therapy in intermittent claudication].
    Laurora G, Corsi M, Bucci M, Cesarone MR, Belcaro G, Dugall M.
    Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):21-9. PubMed ID: 10658441
    [Abstract] [Full Text] [Related]

  • 3. [Global analysis of data from studies with PDE1 alpha-cyslodextrin].
    Laurora G, Belcaro G, Cesarone MR, Incandela L, De Sanctis MT, Dugall M.
    Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):65-8. PubMed ID: 10658448
    [Abstract] [Full Text] [Related]

  • 4. [Treatment of severe intermittent claudication: ORACLE-PGE1 short term study. A randomised 40-week study. Evaluation of efficacy and costs].
    Cesarone MR, Belcaro G, Nicolaides AN, Griffin M, Geroulakos G, Ramaswami G, Cazaubon M, Barsotti A, Vasdekis S, Christopoulos D, Agus G, Bavera P, Mondani P, Ippolito E, Flenda F.
    Minerva Cardioangiol; 2002 Dec; 50(6):683-90. PubMed ID: 12473989
    [Abstract] [Full Text] [Related]

  • 5. [Increasing transcutaneous PO2 in arteriopathies during treatment with PGE1 alpha-cyclodextrin].
    Belcaro G, Cesarone MR.
    Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):37-43. PubMed ID: 10658443
    [Abstract] [Full Text] [Related]

  • 6. [Analysis of costs and results of prostaglandin (PGE1 alpha-cyclodestrin) therapy of peripheral arterial diseases].
    Bucci M, Iacobitti P, Laurora G, Cesarone MR.
    Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):9-15. PubMed ID: 10658439
    [Abstract] [Full Text] [Related]

  • 7. Effects of a 4-week treatment with prostaglandin E1 on plasma endothelin-1 release in patients with intermittent claudication.
    Mangiafico RA, Malatino LS, Santonocito M, Messina R, Attinà T, Dell'Arte S, Sarnataro F.
    Int J Clin Pharmacol Ther; 1999 Jul; 37(7):347-51. PubMed ID: 10442509
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of a short-course intensive rehabilitation program in patients with moderate-to-severe intermittent claudication.
    Ambrosetti M, Salerno M, Tramarin R, Pedretti RF.
    Ital Heart J; 2002 Aug; 3(8):467-72. PubMed ID: 12407823
    [Abstract] [Full Text] [Related]

  • 9. [Severe intermittent claudication: PGE1 treatment. A 40-week registry, efficacy and costs].
    Luzzi R, Belcaro G, Ippolito E, Dugall M, Cesarone MR, Scoccianti M, Errichi BM, Pellegrini L, Ciammaichella G, Ledda A, Ricci A, Cornelli U, Feragalli B, Hosoi M, Corsi M, Simeone E, Agus GB.
    Minerva Cardioangiol; 2012 Aug; 60(4):405-13. PubMed ID: 22858918
    [Abstract] [Full Text] [Related]

  • 10. [Reduction of cardiovascular morbidity/mortality in arteriopathies treated ith PGE1 alpha-cyclodextrin].
    Belcaro G, Bucci M, Cesarone MR, Incandela L, De Sanctis MT.
    Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):51-4. PubMed ID: 10658445
    [Abstract] [Full Text] [Related]

  • 11. Improvement of the walking ability in intermittent claudication due to superficial femoral artery occlusion with supervised exercise and pneumatic foot and calf compression: a randomised controlled trial.
    Kakkos SK, Geroulakos G, Nicolaides AN.
    Eur J Vasc Endovasc Surg; 2005 Aug; 30(2):164-75. PubMed ID: 15890545
    [Abstract] [Full Text] [Related]

  • 12. ["Responders and non-responders" to PGE1 and alpha-cyclodextrin].
    De Sanctis MT, Incandela L, Iacobitti P.
    Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):31-6. PubMed ID: 10658442
    [Abstract] [Full Text] [Related]

  • 13. [Cardiovascular morbidity/mortality modified by the use of FGE1 alpha-cyclodextran and calcium heparin in patients with severe vascular diseases].
    Belcaro G, Cesarone MR, Bucci M, Iacobitti P, Dugall M.
    Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):55-8. PubMed ID: 10658446
    [Abstract] [Full Text] [Related]

  • 14. Treatment of severe intermittent claudication with PGE1--a short-term vs a long-term infusion plan--a 20 week, European randomized trial--analysis of efficacy and costs.
    Belcaro G, Laurora G, Nicolaides AN, Agus G, Cesarone MR, DeSanctis MT, Incandela L, Ricci A, Cazaubon M, Ippolito E, Barsotti A, Vasdekis S, Ledda A, Iacobitti P, Christopoulos D, Errichi BM, Helmis H, Cornelli U, Ramaswami G, Bucci M, Ferrari PG, Corsi M, Pomante P, Mezzanotte L, Geroulakos G.
    Angiology; 1998 Nov; 49(11):885-94; discussion 895. PubMed ID: 9822044
    [Abstract] [Full Text] [Related]

  • 15. PGE(1) treatment of severe intermittent claudication (short-term versus long-term, associated with exercise)--efficacy and costs in a 20-week, randomized trial.
    Belcaro G, Nicolaides AN, Agus G, Cesarone MR, Geroulakos G, Pellegrini L, De Sanctis MT, Incandela L, Ricci A, Mondani P, De Angelis R, Ippolito E, Barsotti A, Vasdekis S, Ledda A, Christopoulos D, Errichi BM, Helmis H, Cornelli U, Ramaswami G, Dugall M, Bucci M, Martines G, Ferrari PG, Corsi M, Di Francescantonio D.
    Angiology; 2000 Aug; 51(8 Pt 2):S15-26. PubMed ID: 10959507
    [Abstract] [Full Text] [Related]

  • 16. Midterm results of prostaglandin E1 treatment in patients with lumbar spinal canal stenosis accompanied by intermittent claudication.
    Nakanishi K, Tanaka M, Misawa H, Takigawa T, Ozaki T.
    Spine (Phila Pa 1976); 2008 Jun 01; 33(13):1465-9. PubMed ID: 18520942
    [Abstract] [Full Text] [Related]

  • 17. Treatment of severe intermittent claudication with pentoxifylline: a 40-week, controlled, randomized trial.
    Cesarone MR, Belcaro G, Nicolaides AN, Griffin M, De Sanctis MT, Incandela L, Geroulakos G, Ramaswami G, Cazaubon M, Barsotti A, Vasdekis S, Bavera P, Ippolito E.
    Angiology; 2002 Jun 01; 53 Suppl 1():S1-5. PubMed ID: 11865828
    [Abstract] [Full Text] [Related]

  • 18. Nomograms used to define the short-term treatment with PGE(1) in patients with intermittent claudication and critical ischemia. The ORACL.E (Occlusion Revascularization in the Atherosclerotic Critical Limb) Study Group. The European Study.
    Belcaro G, Nicolaides AN, Cipollone G, Laurora G, Incandela L, Cazaubon M, Barsotti A, Ledda A, Errichi BM, Cornelli U, Dugall M, Corsi M, Mezzanotte L, Geroulakos G, Fisher C, Szendro G, Simeone E, Cesarone MR, Bucci M, Agus G, De Sanctis MT, Ricci A, Ippolito E, Vasdekis S, Christopoulos D, Helmis H.
    Angiology; 2000 Aug 01; 51(8 Pt 2):S3-13; discussion S14. PubMed ID: 10959506
    [Abstract] [Full Text] [Related]

  • 19. [Rehabilitation program in patients with moderate-to-severe intermittent claudication: immediate results and one year follow-up].
    Rossini D, Bulckaen M, Di Marco S, Giovannetti R, Giuntoli F, Lacopetti L, Vergoni W.
    Monaldi Arch Chest Dis; 2007 Jun 01; 68(2):110-4. PubMed ID: 17886772
    [Abstract] [Full Text] [Related]

  • 20. Effects of intravenous lipoprostaglandin E1 on neurogenic intermittent claudication.
    Murakami M, Takahashi K, Sekikawa T, Yasuhara K, Yamagata M, Moriya H.
    J Spinal Disord; 1997 Dec 01; 10(6):499-504. PubMed ID: 9438815
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.